Nonrandomized Retrospective Studies of Medical Therapy to Prevent Progression of Calcific Aortic Stenosis.

First Author, Year	No. of Subjects	Mean Age (% Male)	Mean F/U Interval	Study Groups	Parameter Reported	P
EBT calcium
Pohle 200111	104	65 y (86)	1.25 y		Increase in valve calcium (per year)
				LDL ≤130 mg/dL	9 ±22%	≤0.001
				LDL >130 mg/dL	43 ±44%
Shavelle 200212	65	67 y	2.5 y		Increase in valve calcium (per year)
				Statin therapy (43%)	12.1%	0.006
				No statin therapy	32%
Echocardiography
Aronow 200114	180	82 y (31)	2.8 y		Increase in peak gradient (mm Hg/y)
				LDL ≥125 mg/dL, not on statin	6.3±1.4	<0.0001
				LDL ≥125 mg/dL, on statin	3.4±1.0
				LDL <125 mg/dL, not on statin	3.1 ±1.1
Novaro 200115	174	68 y (44)	1.8 y		Decrease in valve area (cm2/y)	0.03
				Statin therapy (33%)	0.06±0.16
				No statin therapy	0.11 ±0.18
Bellamy 200213	156	77 y (58)	3.7 y		Decrease in valve area (cm2/y)	0.04
				Statin therapy (24%)	0.04±0.15
				No statin therapy	0.09±0.17
Rosenhek 200410	211	70 y (51)	2.0 y		Increase in aortic velocity (m · s−1·y−1)
				Statin therapy	0.10±0.41	0.0001
				No statin therapy	0.39±0.42
				ACE inhibitor	0.29±0.44	0.29
				No ACE inhibitor	0.35±0.44

EBT indicates electron-beam tomography.